Clinical trial
Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed…
NCT00127049 · Gustave Roussy, Cancer Campus, Grand Paris, Other · Unknown status
Key facts
| NCT number | NCT00127049 |
|---|---|
| Title | Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors |
| Official title | A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis |
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Germ Cell Tumor |
| Intervention type | Drug |
| Interventions | gemcitabine, ifosfamide, cisplatin, G-CSF |
| Enrollment | 37 |
| Start date | Dec 1, 2004 |
| First posted | Aug 5, 2005 |
| Last update posted | Sep 8, 2006 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: